Allergic Conjunctivitis Market
Allergies are the most common chronic conditions in the world and
can lead to life-threatening reactions. Allergy is an exaggerated response to
any foreign substance by the Immune system. Many population-based studies show
that with the change in geographical regions, the prevalence of allergic
disorders vary.
The past two decades saw an increase in the Allergic disorders
prevalence especially in the younger population who are more or less influenced
by western lifestyle. The immunologic basis of allergic diseases is either the
development of memory T and B cells and IgE- antibody production by the immune
system. Allergies can be due to several things like food, environment, grass,
birch, dogs, drugs and others.
Statistics say approximately 60 million Americans suffer from
allergic diseases. Some of the most prevalent allergic diseases are allergic
rhinitis (hay fever), food allergy, and atopic dermatitis (eczema), the most
common cause of among all age groups in the United States.
Worldwide, adverse drug reactions may affect up to 10% of the
world’s population and affect up to 20% of all hospitalized patients.
Allergies affect almost 40% of the population
worldwide.
Allergies are the
result of unwanted intrusion or invaders in the body that immune system creates
a response against. Allergies affects people of all age groups, gender and
country. However, the traits are prevalent more in the people who have a family
history of being susceptible to allergies.
When there is an
entry of foreign substance like pollen, dust particles, or mould, the eye
becomes itchy, red, swells up and begins to water. These are the of symptoms
Allergic conjunctivitis (AC). The tissue lining between inside of the eyelid
and outside of the eyeball known as conjunctiva gets inflamed and results in
the overreaction of the immune system.
At present, the
Allergic conjunctivitis therapeutic market is driven by corticosteroids,
topical vasoconstrictors and dual action antihistamines/mast cell stabilizers, observed
DelveInsight, a Biotech and Pharma Consulting company. Drugs such as
Decongestants, a product by Lotemax, Alrex, Mast cell stabilizers co-developed
by Alocril, and Pataday, dual action antihistamines jointly eveloped by Patanol,
Beprev and many more have impacted the Allergic conjunctivitis therapy market
in a positive way.
DelveInsight’s
analysts observed that emerging Allergic conjunctivitis therapies such as
Zerviate under trials by Nicox Pharma, Aldeyra’s Reproxalap Ocular (ADX-102),
PRT-2761 under-development by ORA, Inc., Ocular’s OTX-DP, DE114A by Santen
Pharma and Bilastine under simulations by Faes Farma are being considered some
of the promising Allergic conjunctivitis therapies. The Allergic conjunctivitis
pipeline has the potential to bring relief instantly and has their trials have
shown that they were able to reduce the Allergic conjunctivitis development to
a huge extent. The Allergic conjunctivitis upcoming therapies are poised to
bring a significant positive shift in the Allergic Conjunctivitis market size.
Several pharma
companies like Nicox Pharma, Aldeyra Therapeutics, ORA, Inc., Ocular
Therapeutix, and Faes Farma and many others are working towards advancing the
Allergic conjunctivitis pipeline. The Allergic conjunctivitis market is going
to advance further due to the potential pipeline underway and the increase in
Allergic conjunctivitis prevalence.
Comments
Post a Comment